While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Key Facts Eli Lilly’s shares dropped more than 14% to around $639 as of about 2:25 p.m. EDT, marking what would be the company’s steepest single-day loss since a 29% decline on Aug. 8, 2000.

Eli Lilly’s shares dropped more than 14% to around $639 as of about 2:25 p.m. EDT, marking what would be the company’s steepest single-day loss since a 29% decline on Aug. 8, 2000.

Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly CEO David Ricks ...